Ivermectin and fenbendazole are both antiparasitic drugs, but they sit in very different regulatory categories in the United States. Ivermectin is an FDA-approved human medicine for specific parasitic infections, while fenbendazole is a veterinary dewormer that has never been approved for people in any form or for any purpose. Interest in taking the two together comes almost entirely from social media claims about cancer — not from completed human trials.

This article summarizes what the published research on ivermectin and fenbendazole actually shows, what it does not show, and what regulators and medical bodies currently say. If you are looking for the basics of the approved human drug instead, our overview of what ivermectin is approved to treat and its known side effects covers that ground. State access laws and retail availability changed repeatedly through 2025 and into 2026; the legal details here were last verified in late September 2026.

Key takeaways

  • Ivermectin tablets are FDA-approved for two parasitic infections; fenbendazole is labeled for animal use only and is not approved for human use.
  • Laboratory and animal studies have reported anticancer activity for both drugs, but there are no completed large human trials showing benefit.
  • Published case reports describe severe liver injury in people who self-administered fenbendazole, including one case involving fenbendazole and ivermectin taken together.
  • A small number of states now allow pharmacists to supply human ivermectin without a prescription; no state has changed fenbendazole's status.
  • Legal access is not the same as evidence of benefit, and no state law includes dosing instructions.

What ivermectin and fenbendazole are (approved uses)

A pharmacist's gloved hands counting small white tablets on a stainless steel pill counting tray with a spatula.

Ivermectin

Ivermectin is an antiparasitic drug discovered in the 1970s. Ivermectin tablets (Stromectol) are FDA-approved to treat strongyloidiasis of the intestinal tract and onchocerciasis (river blindness); ivermectin cream (Soolantra) is FDA-approved for rosacea, and ivermectin lotion (Sklice) is a treatment for head lice, while tablets are also used off-label for scabies and other parasites. It works by binding glutamate-gated chloride channels in parasites, causing paralysis, and does not readily affect mammals because it normally cannot enter the mammalian central nervous system. The topical products are a separate category with their own labeling, which we cover in our guide to topical ivermectin formulations.

Fenbendazole

Fenbendazole is a benzimidazole anthelmintic. The American Cancer Society describes it as a deworming medicine that treats parasitic infections in animals including dogs, cattle, goats and horses, notes that it has not been tested in human studies, and states that it is intended for use in animals only. The FDA has never approved fenbendazole for humans for any purpose, and scientific data on whether it is safe and effective in people does not exist. Its mechanism involves inhibiting microtubule polymerization and blocking glucose uptake in susceptible parasites.

Where mebendazole fits in

People searching for ivermectin and mebendazole are usually looking at the same idea from a different angle. Mebendazole is the benzimidazole that is approved in the US as a human medicine for intestinal worm infections such as pinworm, which is why some clinicians and researchers consider it a more plausible research candidate than its veterinary cousin. Being an approved human drug, however, says nothing about whether an ivermectin mebendazole combination works for anything outside its labeling.

Drug Approved for humans in the US? Labeled uses
Ivermectin (oral) Yes, by prescription Intestinal strongyloidiasis; onchocerciasis
Ivermectin (topical) Yes Rosacea; head lice
Mebendazole Yes, by prescription Intestinal worm infections such as pinworm
Fenbendazole No — animal use only Parasites in dogs, cattle, goats, horses

What laboratory and clinical research currently shows

Gloved researcher hands pipetting into a clear multiwell cell culture plate during laboratory drug testing.

Cell and animal studies

Most of the interest in ivermectin fenbendazole combinations traces back to preclinical work. A 2025 review in an NIH-indexed journal reports that across diverse tumor models ivermectin shows antitumor activity through induction of apoptosis, oxidative stress, mitochondrial dysfunction and inhibition of signaling pathways including NF-κB, mTOR/STAT3 and importin β, with immunomodulatory effects suggesting possible synergy with immunotherapies. The same review notes that preclinical studies have shown tumor volume reductions of more than 50% in mouse models. Fenbendazole has been studied along broadly similar microtubule-disrupting lines.

Human evidence

Here the picture changes sharply. A 2025 review indexed in PubMed concludes that while preclinical studies demonstrate anticancer effects across various cancers, clinical evidence in humans is limited, with no large-scale randomized controlled trials confirming therapeutic benefit. That review also flags observational reports of toxicity in oncology patients who self-medicated after seeing social media claims.

New research activity

Research interest is real and ongoing. Reporting in oncology trade press describes that the National Cancer Institute has initiated preclinical research to further evaluate ivermectin's anticancer properties — preclinical, meaning laboratory work that precedes human testing. Coverage of that decision notes that in some cases the ivermectin concentrations required for antitumor effects in vitro exceed what can safely be achieved in humans, and that preclinical studies generate hypotheses rather than establishing efficacy, dosing or safety.

What the research does not show

A gloved hand holding a plastic veterinary paste dosing syringe, a product labeled for animal use only.
  • It does not show that either drug treats cancer in people. Promising preclinical results come from cell cultures and animals, not humans, and cannot establish that ivermectin helps treat cancer in people.
  • It does not show anything about the combination. Published work on ivermectin and fenbendazole pills taken together as a protocol is essentially absent. Combining two agents does not inherit evidence from either one, and it doubles the number of unknowns.
  • It does not support anecdotes as evidence. The widely shared story behind the fenbendazole trend involved a patient who was simultaneously enrolled in a clinical trial receiving the approved immunotherapy pembrolizumab, a drug that produces dramatic remissions in some lung cancer patients — meaning the effect of the trial drug and the dewormer cannot be separated.
  • It does not support COVID-19 use. The FDA has not approved any form of ivermectin for COVID-19, and no data have shown it effective for treating or preventing it.
  • It does not establish a dose. There is no validated human dosing for fenbendazole at all, and approved ivermectin dosing schedules are calculated for parasitic infections, not for any other purpose.

Known safety risks and interactions

A pharmacist hands a small white paper prescription bag across the counter to a waiting customer's hands.

Documented liver injury

The clearest human safety signal for fenbendazole is hepatic. A 2024 case report in the ACG Case Reports Journal describes the first histologically confirmed case of severe drug-induced liver injury, hepatocellular pattern, associated with self-administration of fenbendazole in a 67-year-old woman who presented with two weeks of jaundice; her liver function tests normalized three months after stopping the drug. A 2025 case presentation to the American College of Gastroenterology reported a 68-year-old man with hepatocellular carcinoma and MASH cirrhosis who developed eight days of progressive jaundice and fatigue, and the authors noted that no human data confirm fenbendazole's safety or efficacy and that cirrhotic patients are especially vulnerable to hepatotoxicity because of limited hepatic reserve.

Most directly relevant here, a 2026 case report describes drug-induced liver injury after co-ingestion of veterinary fenbendazole and ivermectin for prostate cancer. After both agents were stopped, transaminase levels fell 58% within nine days and normalized within six weeks, and a RUCAM causality score of 9 indicated a "highly probable" causal relationship between the anthelmintics and the acute liver injury. Fenbendazole in that setting was a product labeled for animal use only and not approved for people.

Interactions and populations at risk

GoodRx notes that ivermectin tablets should be used with caution with blood thinners such as warfarin because ivermectin can itself thin the blood and raise bleeding risk, and that ivermectin tablets should be avoided in pregnancy, since animal studies have shown birth defects such as cleft palate at high doses. The FDA has also warned that ivermectin is dangerous in large doses.

Animal products are not a substitute

Veterinary pastes, gels and drenches are formulated for animal body weights and are labeled for animal use only; they are not approved for human use. Pharmacy Times reporting on the state-law changes notes that people were purchasing formulations of the drug intended for animals.

Regulatory status and medical guidance

Federal status

Federally, nothing has changed the core picture: oral ivermectin remains a prescription drug for its approved parasitic indications, and the FDA continues to state that ivermectin is not approved or authorized for COVID-19 treatment based on available clinical trial data. Fenbendazole remains unapproved for humans.

State laws (verified late September 2026)

Several states have changed how human ivermectin is supplied. Tennessee was first in 2022 with SB 2188/HB 2746; Arkansas passed SB 189 and Act 396 on March 25, 2025, and Idaho passed SB 1211 on April 14, 2025, both stating that ivermectin may be sold or purchased over the counter without a prescription or consultation with a health care professional. Louisiana's SB 19 and Act 464 took effect June 20, 2025, allowing pharmacists to dispense ivermectin to adults under a standing order from a health care professional with prescriptive authority, with a requirement to provide information on indications and contraindications. A later state-by-state summary adds Texas HB 25, a pharmacist-dispensing model effective December 4, 2025, and notes that roughly half a dozen more states have active bills, that a prescription is required everywhere else, and that individual pharmacists may decline to dispense or stock it even where state law allows.

Two practical caveats matter more than the headlines. Reports note that none of the state laws include dosing guidance, and that pharmacies and retailers remain free to decide whether to stock or dispense ivermectin, so legal permission does not guarantee availability at any given store. Pricing likewise varies by pharmacy, state and whether a generic is stocked; check a current pharmacy price tool rather than relying on figures quoted in older articles. None of these laws apply to fenbendazole, which remains a veterinary product.

What clinicians advise

Pharmacy organizations have raised concerns about self-medication and the difficulty of advising patients without FDA over-the-counter labeling for dosage and interactions. If you are in cancer treatment, tell your oncology team about anything you are taking — clinicians are specifically advised to ask about alternative therapies in patients with abnormal liver tests.

Frequently asked questions

Are ivermectin and fenbendazole pills for humans sold in pharmacies?

Human-labeled ivermectin tablets are, by prescription in most states and through pharmacist dispensing in a few. Fenbendazole has no human-labeled pill: products sold for people online are unapproved, and the drug itself is approved only for animals.

Is taking fenbendazole ivermectin together more effective than either alone?

There is no completed human trial testing that combination for any condition beyond parasitic infection, so the honest answer is that no one knows. The only published human data on the pair is a liver-injury case report.

Does the NCI studying ivermectin mean it works?

No. The NCI work described in trade reporting is preclinical, which is the earliest stage of investigation and frequently does not translate into human benefit.

Is ivermectin and mebendazole a safer combination than fenbendazole?

Both are approved human drugs, which means their side-effect profiles at labeled doses are documented. That is not the same as evidence that combining them treats anything they are not approved for.

What about topical ivermectin?

Topical products are approved for rosacea and head lice only, and none of the cancer-related claims apply to them.

Sources